ACADEMICS IN RESIDENCE
Academic research groups whose research interests are aligned with ours, are housed in the Centre for Pathway Analysis. Our Milner Therapeutics Consortium pharma partners also have a physical presence, through scientists working on collaborative projects with Cambridge researchers and through hot-desking.
Below you will find details of academics who currently reside within the Milner Therapeutics Institute.
KONSTANTINOS TZELEPIS
The Tzelepis group is focusing on the discovery of novel therapeutic targets and the bench-to-clinic transition of new treatments for aggressive malignancies including acute myeloid leukaemia (AML). Dr Tzelepis’s recent work has led to the development of sophisticated CRISPR screening platforms which formed the basis for his follow-up studies that identified the role of several new cancer vulnerabilities including the RNA methyltransferase METTL3 and the splicing kinase SRPK1. Now, his group is investigating how the structures and modifications of the RNA regulate the initiation and maintenance of devastated diseases.
MANAV PATHANIA
The Pathania group (Milner Therapeutics Institute, Dept Oncology and CRUK Cambridge Centre) have a central focus on developing new mouse models for children’s brain tumours, to better understand the diverse genetic basis of different brain tumour types. By applying CRISPR technology to test genetic and epigenetic weaknesses in these tumour models, they hope in the longer term to pave the way to more targeted, precise treatments that can be tailored to each patient. A key area of interest includes how dynamic chromatin remodelling is regulated in neural stem cells and how it becomes co-opted in brain cancer, including paediatric high-grade glioma.
